About LENZ Therapeutics, Inc.
https://www.lenz-tx.comLENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
CEO
Evert Schimmelpennink
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-03-22 | Reverse | 1:7 |
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:791.55K
IWM
Weight:0.01%
Shares:387.62K
XSU.TO
Weight:0.01%
Shares:387.62K
Summary
Showing Top 3 of 104
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:4.18M
Value:$77.68M
ALPHA WAVE GLOBAL, LP
Shares:3.61M
Value:$67.15M
VERSANT VENTURE MANAGEMENT, LLC
Shares:2.66M
Value:$49.39M
Summary
Showing Top 3 of 169
About LENZ Therapeutics, Inc.
https://www.lenz-tx.comLENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $12.5M ▲ | $31.26M ▲ | $-16.7M ▼ | -133.6% ▲ | $-0.59 ▼ | $-16.57M ▲ |
| Q2-2025 | $5M ▲ | $21.86M ▲ | $-14.91M ▼ | -298.24% ▼ | $-0.53 | $-16.84M ▲ |
| Q1-2025 | $0 | $16.93M ▲ | $-14.62M ▼ | 0% | $-0.53 ▼ | $-16.89M ▼ |
| Q4-2024 | $0 | $15.22M ▲ | $-12.65M ▼ | 0% | $-0.46 ▼ | $-15.2M ▼ |
| Q3-2024 | $0 | $12.95M | $-10.21M | 0% | $-0.38 | $-12.94M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $202.17M ▼ | $210.7M ▼ | $16.78M ▲ | $193.93M ▼ |
| Q2-2025 | $209.52M ▲ | $217.33M ▲ | $10.97M ▲ | $206.37M ▲ |
| Q1-2025 | $193.98M ▼ | $201.25M ▼ | $9.24M ▼ | $192.01M ▼ |
| Q4-2024 | $209.03M ▼ | $215.3M ▼ | $11.22M ▲ | $204.08M ▼ |
| Q3-2024 | $217.11M | $224.01M | $8.73M | $215.28M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-16.7M ▼ | $-8.59M ▲ | $-4.33M ▼ | $598K ▼ | $-12.32M ▼ | $-9.03M ▲ |
| Q2-2025 | $-14.91M ▼ | $-11.51M ▲ | $-414K ▼ | $26.49M ▲ | $14.57M ▲ | $-11.75M ▲ |
| Q1-2025 | $-14.62M ▼ | $-16.05M ▼ | $18.89M ▲ | $44K ▼ | $2.88M ▲ | $-16.16M ▼ |
| Q4-2024 | $-12.65M ▼ | $-9.08M ▲ | $-11.86M ▲ | $53K ▼ | $-20.89M ▲ | $-9.23M ▲ |
| Q3-2024 | $-10.21M | $-10.58M | $-62.23M | $29.82M | $-42.99M | $-10.77M |
CEO
Evert Schimmelpennink
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-03-22 | Reverse | 1:7 |
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:791.55K
IWM
Weight:0.01%
Shares:387.62K
XSU.TO
Weight:0.01%
Shares:387.62K
Summary
Showing Top 3 of 104
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:4.18M
Value:$77.68M
ALPHA WAVE GLOBAL, LP
Shares:3.61M
Value:$67.15M
VERSANT VENTURE MANAGEMENT, LLC
Shares:2.66M
Value:$49.39M
Summary
Showing Top 3 of 169